Alnylam Pharmaceuticals heads into its July 30 earnings print with the Street broadly bullish but steadily marking down its price targets — a week after the stock shed 3.5% to $271.37.
The analyst picture is the clearest signal this week. Confidence in the direction hasn't shifted — every recent move has maintained a Buy or Overweight rating — but conviction on valuation has clearly softened. JP Morgan trimmed its target from $420 to $400 on July 22 while holding Overweight. Bank of America cut from $460 to $410 the week prior, and Truist moved from $505 to $410. Morgan Stanley, the lone neutral voice, actually nudged its Equal-Weight target higher to $400 from $370. The consensus mean now sits near $432, implying around 59% upside from current levels — a gap that reflects how far the stock has fallen year-to-date rather than fresh optimism from the Street. That $160 implied upside deserves a footnote: ALNY has lost roughly a third of its value this year, so the headline potential is as much a function of price decay as analyst conviction.
The bear case centres on net price pressure across the TTR franchise — a structural headwind that the bulls acknowledge but frame as temporary. The bull case leans on RNAi platform depth, pipeline breadth, and the longer-term commercial expansion story. Factor scores add nuance: EPS momentum over 90 days ranks in the 71st percentile, suggesting forward estimate revision has been constructive, while the 12-month forward EPS year-on-year growth rank trails at just 34 — consistent with analysts modelling near-term margin drag from pricing normalization before pipeline optionality kicks in. The PE multiple has compressed about 1.6 points over 30 days to 23.3x, tracking the stock lower without a meaningful re-rating in either direction.
Positioning is conspicuously relaxed given the stock's weakness. Short interest at 4.2% of free float has drifted up roughly 2% over the past month — a modest rebuild, not an assault. The borrow market is loose: availability runs at roughly 4,099% of short interest, meaning lenders hold around 85 million shares available against the 5.6 million currently borrowed. Borrowing costs remain near record lows at 0.44%, up 7% on the week but a fraction of what a crowded short looks like. Options tell a similar story — the put/call ratio at 0.51 is almost exactly in line with its 20-day average of 0.49, with a z-score barely above zero. There is no hedging panic ahead of the print. Peers SRPT and CRSP fell 9.7% and 4.6% respectively on the week, while ALNY's 3.5% decline looks contained by comparison.
The institutional ownership picture adds one detail worth noting. T. Rowe Price added over 3.1 million shares in the most recent reported quarter — the largest change among top holders — bringing their stake to just under 5% of shares outstanding. Capital Research remains the dominant holder at 15.3%, and FMR (Fidelity) added 760,000 shares to reach 10.6%. That level of concentrated long-side institutional ownership, combined with near-zero short pressure and loose borrow, means any sharp move after earnings is likely to be driven by the fundamental reaction rather than positioning dynamics.
Recent earnings reactions have been modest. The last three prints produced first-day moves of +2.1%, -2.6%, and -1.7% — a tight band suggesting the market has generally priced Alnylam's quarterly updates efficiently. The five-day window has been similarly contained. The July 30 release is therefore less about whether RNAi adoption is growing and more about whether Alnylam can give the Street enough confidence that net price headwinds are stabilising — which is the specific question analysts have been sharpening their pencils around all week.
See the live data behind this article on ORTEX.
Open ALNY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
